SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers.
Antibodies, Viral
/ blood
Asymptomatic Infections
/ epidemiology
BNT162 Vaccine
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
/ statistics & numerical data
COVID-19 Vaccines
/ administration & dosage
Case-Control Studies
Female
Health Personnel
/ statistics & numerical data
Humans
Immunization Schedule
Incidence
Male
Prospective Studies
RNA, Viral
/ genetics
SARS-CoV-2
/ genetics
Severity of Illness Index
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
received:
17
06
2021
accepted:
17
09
2021
entrez:
16
10
2021
pubmed:
17
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58-93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p = 0.01). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection.
Identifiants
pubmed: 34654808
doi: 10.1038/s41467-021-26154-6
pii: 10.1038/s41467-021-26154-6
pmc: PMC8521593
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Viral
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6032Subventions
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : COVID-2020-12371817
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : COVID-2020-12371760
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003650
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003650
Organisme : Fondazione Cariplo (Cariplo Foundation)
ID : 2020-1374
Informations de copyright
© 2021. The Author(s).
Références
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
Clin Microbiol Infect. 2021 Jul;27(7):1029-1034
pubmed: 33813122
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Rev Med Virol. 2021 May 27;:e2260
pubmed: 34043841
Nat Commun. 2021 Jan 19;12(1):434
pubmed: 33469026
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Travel Med Infect Dis. 2021 Mar-Apr;40:102002
pubmed: 33647467
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
N Engl J Med. 2020 May 7;382(19):1851-1852
pubmed: 32187463
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Int J Infect Dis. 2021 Aug;109:199-202
pubmed: 34242763
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246